AbbVie says its experimental blood-cancer treatment etentamig met the primary goals of a Phase 3 study in people with relapsed or refractory multiple myeloma. The etentamig trial topline results were announced on September 3, 2026.
In the CERVINO study, AbbVie reported an objective response rate of 74% for etentamig compared with 45.7% for standard treatment. The company also said the therapy reduced the risk of disease progression or death by 60%.
What the etentamig trial measured
Objective response rate measures the proportion of participants whose cancer shrinks by a defined amount under trial criteria. Progression-free survival measures how long people live without the disease worsening or death occurring.
AbbVie also reported one-year overall survival of 87.9% in the etentamig group compared with 72% for the control group. These are company-released topline findings; full study data and detailed safety results are needed for independent assessment.
How the therapy is designed to work
Etentamig is a bispecific therapy designed to engage T cells and direct them toward proteins associated with multiple-myeloma cells. The approach aims to use the immune system to recognise and attack the cancer.
Multiple myeloma is a cancer of plasma cells and often follows cycles of response and relapse. Patients whose disease returns after treatment can have fewer effective options, which is why comparative late-stage studies are important.
Results are not yet regulatory approval
Meeting trial endpoints does not itself make an experimental medicine approved or available. Regulators must review efficacy, safety, manufacturing and benefit-risk evidence before deciding whether to authorise a treatment.
Detailed adverse-event rates were not fully described in the initial reports. Bispecific immune therapies can carry important risks, so conclusions about comparative safety should wait for a complete presentation and regulatory review.
The announcement supports further evaluation of etentamig as a potential multiple-myeloma treatment. Patients should not change therapy based on topline corporate results and should discuss approved options and clinical trials with their oncology teams.
